Recently, in a randomized phase II trial investigating the effect of different nivolumab doses (0.3, 2 or 10 mg/kg) in mRCC patients previously treated with agents targeting the vascular endothelial growth factor pathway, 36 patients were treated beyond progression and 25 of them (69%) experienced durable response consisting in tumor reduction or stabilization [25]. The gene discussed is VEGFA; the disease is neoplasm.